Calidar

Calidar is a pre-clinical stage biotechnology company focused on developing novel therapeutic agents for the treatment of advanced prostate cancer. The company's primary research efforts center on the discovery of next-generation small molecule inhibitors targeting the androgen receptor, specifically designed to overcome resistance mechanisms observed with current standard-of-care treatments. By utilizing advanced medicinal chemistry and structural biology, Calidar aims to develop potent antagonists that remain effective in the presence of common androgen receptor mutations and splice variants. The company is currently advancing its lead candidates through early-stage validation and optimization to address the significant unmet medical need in castration-resistant prostate cancer.